Emory University
Atlanta, Georgia, 30303, United States
NCT Number: NCT01035580
The main objective of this study is to determine the maximum tolerable dose and safety of intravaginal curcumin in a normal population of women (women with no evidence of cervical cytological abnormalities by pap testing).
Looking for future studies?
Notify Me18 year–45 year
Female
Interventional
Phase 1
Atlanta, Georgia, 30303, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Curcumin 500 mg capsules will be inserted intravaginally once daily for 14 days for a maximum daily dosage of 2000 mg
Time frame: 14 days
Emory University
Other
Phase I Trial on Safety and Pharmacokinetics of Intravaginal Curcumin in Normal Female Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01639820
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Bron, France
View Trial DetailsNCT03763565
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Bangkok, Thailand
View Trial DetailsNCT04415840
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Dortmund, North Rhine-Westphalia, Germany
View Trial DetailsNCT04326049
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Herne, North Rhine-Westphalia, Germany
View Trial Details